Karyopharm Therapeutics Inc.
$8.94
▲
1.2%
2026-04-21 07:45:02
www.karyopharm.com
NMS: KPTI
Explore Karyopharm Therapeutics Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$193.06 M
Current Price
$8.94
52W High / Low
$10.99 / $3.65
Stock P/E
—
Book Value
$-16
Dividend Yield
—
ROCE
-554.58%
ROE
81.86%
Face Value
—
EPS
$-17.93
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
228
Beta
0.4
Debt / Equity
-0.8
Current Ratio
1.12
Quick Ratio
1.08
Forward P/E
-1.83
Price / Sales
1.23
Enterprise Value
$388.95 M
EV / EBITDA
-4.3
EV / Revenue
2.66
Rating
Buy
Target Price
$11
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Pliant Therapeutics, Inc. | $1.29 | — | $79.87 M | — | -74.87% | -61.55% | $1.95 / $1.09 | $2.95 |
| 2. | Biohaven Ltd. | $10.82 | — | $1.65 B | — | -222.16% | -3.11% | $24.06 / $7.48 | $0.39 |
| 3. | Evommune, Inc. | $27.97 | — | $988.7 M | — | -39.16% | -54.42% | $33.2 / $13.88 | $6.52 |
| 4. | Alnylam Pharmaceuticals, Inc. | $310.49 | 133.51 | $41.46 B | — | 14.33% | 73.28% | $495.55 / $228.28 | $5.96 |
| 5. | Eledon Pharmaceuticals, Inc. | $4.14 | — | $314.03 M | — | -55.26% | -35.79% | $4.6 / $1.35 | $1.81 |
| 6. | Rezolute, Inc. | $3.37 | — | $322.5 M | — | -48.84% | -74.02% | $11.46 / $1.07 | $1.23 |
| 7. | Aditxt, Inc. | $0.35 | — | $0.39 M | — | -318.91% | -6.99% | $2,594.48 / $0.39 | $-151.87 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 34.08 M | 44.04 M | 37.93 M | 30.02 M | 30.54 M | — |
| Operating Profit | -17.84 M | -15.22 M | -24.39 M | -33.26 M | -31.28 M | — |
| Net Profit | -102.2 M | -33.13 M | -37.25 M | -23.46 M | -30.78 M | — |
| EPS in Rs | -4.53 | -1.47 | -1.65 | -1.04 | -1.37 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 146.07 M | 145.24 M | 146.03 M | 157.07 M |
| Operating Profit | -90.71 M | -119.44 M | -129.54 M | -142.2 M |
| Net Profit | -196.04 M | -76.42 M | -143.1 M | -165.29 M |
| EPS in Rs | -8.7 | -3.39 | -6.35 | -7.33 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 108.42 M | 164.42 M | 240.44 M | 358.17 M |
| Total Liabilities | 401.34 M | 350.44 M | 376.64 M | 374.83 M |
| Equity | -292.93 M | -186.02 M | -136.21 M | -16.66 M |
| Current Assets | 103.15 M | 156.46 M | 233.92 M | 350.16 M |
| Current Liabilities | 92.06 M | 92.26 M | 69.48 M | 65.91 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -75.37 M | -127.49 M | -92.72 M | -149.55 M |
| Investing CF | 43.38 M | 95.47 M | 7.94 M | -104.26 M |
| Financing CF | 30.05 M | 41.65 M | 1.12 M | 193.74 M |
| Free CF | -75.37 M | -127.63 M | -92.72 M | -149.67 M |
| Capex | — | -0.14 M | — | -0.12 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -0.55% | -7.03% | — | — |
| Earnings Growth % | 46.6% | 13.43% | — | — |
| Profit Margin % | -52.62% | -97.99% | -105.23% | — |
| Operating Margin % | -82.24% | -88.71% | -90.53% | — |
| Gross Margin % | 95.86% | 96.62% | 96.68% | — |
| EBITDA Margin % | -26.58% | -81.09% | -88.69% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-02-26 | 1:0.0666667 |